Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

Bristol-Myers Squibb Company (NYSE: BMY) announced a new agreement to expand access to Reyataz® (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.

Ultra-long-acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego.

The Bristol-Myers Squibb Foundation awarded five grants totaling $1.5 million to organizations that will empower African American women with type 2 diabetes to better manage their disease while also leveraging their standing as leaders in their families and communities to influence the health of those around them.

Merck KGaA announced that following feedback from regulatory authorities the company has decided to no longer pursue the global approval process of Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS).

Amgen (NASDAQ: AMGN) announced the 34 science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the 19th annual Amgen Award for Science Teaching Excellence.

Boehringer Ingelheim and Ashoka will launch a three-year global initiative to improve health in communities around the world.The "Making More Health" initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenge health problems.